The COVID-19 Illness: Addressing the Current Treatment Limitations and Care Gaps with a Novel Alternative and Complementary Agent-the Glutathione-Cyclodextrin Complex
We are approaching the fourth year of the COVID-19 pandemic. Although great progress has been made in addressing the SARS-CoV-2 infection, there are significant treatment limitations and care gaps that need to be addressed in order to more effectively treat patients critically ill with COVID-19 and the large population of patients with post-COVID symptoms. We highlight the significanceof thecytokinestorminthe immunothrombotic process of COVID-19 illness. Finally, we present scientific evidence of the utility of a novel complementary therapeutic agent, the glutathione-cyclodextrin complex, that will likely address those limitations and close those gaps. If confirmed by rigorous clinical trials, the complex will have a significant impact on the treatment of the entire spectrum of COVID-19 illness and contribute to the control or resolution of the COVID-19 pandemic.